Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cutera, Inc. stock logo
CUTR
Cutera
$0.10
$0.04
$0.09
$1.63
$1.96M1.362.97 million shsN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$78.79
+7.6%
$84.00
$60.10
$156.00
$2.53B1.911.07 million shs1.79 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cutera, Inc. stock logo
CUTR
Cutera
0.00%0.00%0.00%0.00%+148.46%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+7.61%+7.07%+19.14%-30.83%-36.46%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cutera, Inc. stock logo
CUTR
Cutera
$0.10
$0.04
$0.09
$1.63
$1.96M1.362.97 million shsN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$78.79
+7.6%
$84.00
$60.10
$156.00
$2.53B1.911.07 million shs1.79 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cutera, Inc. stock logo
CUTR
Cutera
0.00%0.00%0.00%0.00%+148.46%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+7.61%+7.07%+19.14%-30.83%-36.46%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cutera, Inc. stock logo
CUTR
Cutera
0.00
N/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.46
Hold$134.5070.71% Upside

Current Analyst Ratings Breakdown

Latest TMDX and CUTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Boost Price TargetHold$75.00 ➝ $80.00
6/9/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Reiterated RatingHold (C)
5/26/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Reiterated RatingHold
5/26/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetHold$85.00 ➝ $75.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetBuy$152.00 ➝ $124.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetBuy$190.00 ➝ $120.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetHold$130.00 ➝ $85.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetOverweight$160.00 ➝ $120.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetBuy$174.00 ➝ $142.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
DowngradeOutperformMarket Perform
(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cutera, Inc. stock logo
CUTR
Cutera
$155.21M0.01N/AN/A($8.62) per share-0.01
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$605.49M4.50$4.22 per share18.65$13.79 per share5.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cutera, Inc. stock logo
CUTR
Cutera
-$162.83M-$6.58N/AN/AN/A-84.86%N/A-45.07%N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$190.29M$4.4017.9121.83N/A27.04%22.38%8.46%7/30/2026 (Estimated)

Latest TMDX and CUTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.62$0.30-$0.32$0.20$174.44 million$173.93 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cutera, Inc. stock logo
CUTR
Cutera
N/A
2.88
1.86
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.70
6.74
6.19

Institutional Ownership

CompanyInstitutional Ownership
Cutera, Inc. stock logo
CUTR
Cutera
90.70%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Cutera, Inc. stock logo
CUTR
Cutera
0.42%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cutera, Inc. stock logo
CUTR
Cutera
46020.19 million20.10 millionNo Data
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21034.56 million32.18 millionOptionable

Recent News About These Companies

TransMedics Group Inc.
TransMedics Group Signals Growth Amid Margin Squeeze

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cutera stock logo

Cutera NASDAQ:CUTR

Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$78.79 +5.57 (+7.61%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$78.88 +0.09 (+0.11%)
As of 06/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.